Gosset AlpHelix Biosciences General Information
AlpHelix Biosciences specializes in the early discovery of drugs targeting membrane proteins—especially GPCRs—using proprietary technology platforms. The company provides global pharmaceutical partners with services ranging from target preparation and structural determination to hit identification for antibodies, small molecules, and peptides. Their MegaR platform enables efficient production of stable, ligand-free GPCR proteins suitable for high-throughput screening and structure-based drug design. No clinical results are reported as the company operates primarily as a service provider in preclinical research.
Contact Information
China
Drug Pipeline
No pipeline data available
Key Partnerships
DP Technology (AIDD & SBDD platform partnership), HitGen (Small Molecule Drug Discovery partnership)
AlpHelix Biosciences Funding
No funding data available